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Objective: Tuberous sclerosis complex (TSC) is a genetic disorder primarily characterized by the development of multisystem benign tumors. Epilepsy is the most
common neurologic manifestation, affecting 80%-90% of TSC patients. The diffuse
structural brain abnormalities and the multifocal nature of epilepsy in TSC pose diagnostic challenges when evaluating patients for epilepsy surgery.
Methods: We retrospectively reviewed the safety experience and efficacy outcomes
of five adult TSC patients who were treated with direct brain-responsive neurostimulation (RNS System, NeuroPace, Inc).
Results: The average follow-up duration was 20 months. All five patients were responders (≥50% disabling seizure reduction) at last follow-up. The median reduction
in disabling seizures was 58% at 1 year and 88% at last follow-up. Three of the five
patients experienced some period of seizure freedom ranging from 3 months to over
1 year.
Significance: In this small case series, we report the first safety experience and efficacy outcomes in patients with TSC-associated drug-resistant focal epilepsy treated
with direct brain-responsive neurostimulation.
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Key Points
• TSC patients commonly have comorbid drug-resistant epilepsy that is difficult to
treat with epilepsy surgery.
• Five TSC patients were treated with brain-
responsive neurostimulation (RNS
System) for an average of 20 months.
• All five patients experienced >50% seizure frequency reduction at last follow-up.
• Brain-responsive neurostimulation was well tolerated and efficacious in this small
series of TSC patients with focal drug-resistant epilepsy.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
© 2021 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy
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IN TRO D U C T ION

Tuberous sclerosis complex (TSC) has a prevalence of 1 in
6000 people.1 Epilepsy is the most common neurologic condition associated with TSC and has a prevalence of roughly
80%-90%.2,3 Over 60% of TSC patients with epilepsy are
refractory to antiseizure medication (ASM).4 The proportion of TSC patients refractory to ASM is twice that of the
general epilepsy population.5 Infantile spasm is a common
seizure type in TSC patients; however, 68% of TSC patients
have more than one focal onset seizure type, including focal
aware, focal impaired awareness, and focal to bilateral tonic-
clonic seizures.2–4
Resective or ablative surgery is considered the gold standard therapy for TSC-
associated drug-
resistant epilepsy
(TSC-DRE) when a seizure focus or foci can be clearly identified. Tuber resection has shown efficacy in patients with
epileptogenic tubers and has been associated with improved
cognitive outcomes when successful.6–8 However, for many
TSC-DRE patients, focal or tuber resection is not a suitable
option. Numerous seizure foci, difficult to treat seizure foci
(eg, bilateral or near eloquent cortex), and generation of
secondary foci that propagate seizures postoperatively may
contribute to unsuccessful resective or ablative procedures.9
Additionally, seizure foci are not always associated with tubers. These factors make TSC-DRE exceedingly difficult to
manage. Neuromodulation offers new treatment options for
this patient group.
The RNS System (NeuroPace, Inc) delivers direct brain-
responsive neurostimulation to one or two seizure foci in
response to abnormal epileptiform activity detected by the
system. In addition to the efficacy reported during the clinical trials,10 it was also demonstrated that areas of eloquent
cortex could be treated without stimulation side effects.11
There were no patients with diagnosed TSC in the RNS
System clinical trials, perhaps due to the concern that repeated MRI scans would be needed to monitor tuber growth.
Here, we report safety experience and efficacy outcomes for
five cases of TSC-DRE treated with the RNS System.
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METHODS

A retrospective chart review was performed on adult patients
with TSC-DRE across five institutions who were treated with
the RNS System according to the FDA approved indication
for use between November 20, 2016, and October 1, 2019.
Each institution received approval from their respective institutional review boards to perform this review. Inclusion
criteria were a diagnosis of TSC by diagnostic or genetic testing, and treatment with the RNS System for a minimum of
6 months. All patients underwent surgical localization, and
those results guided the location and type of leads implanted.

MCDERMOTT et al.

Demographics, epilepsy histories, RNS System details, serious adverse events and stimulation-related side effects were
collected from the patients’ medical records. Disabling seizure
frequencies were collected from the medical record and reported as an average of seizures per month over the prior year.
The disabling seizure frequencies per month were collected for
the following time-points: preimplant baseline, 1 year postimplantation and last follow-up postimplant. Disabling seizures
were defined as focal aware (with motor component), focal
impaired awareness, or focal to bilateral tonic-clonic seizures.
Changes from baseline disabling seizure frequency were
calculated for 1 year and last follow-up postimplant. Safety
was measured through review of serious adverse events. The
Clinician Global Impression Scale (CGIS) was obtained from
treating physicians to assess patients’ clinical responses to
RNS System treatment as of the last follow-up visit.
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RESULTS

Five adult patients diagnosed with TSC-DRE and focal epilepsy were treated with the RNS System per the FDA indication for use. Demographics, epilepsy history, and RNS
System lead placement can be found in Table 1. The median
age of our patients was 35 years (range: 23-41). No patient
had a history of infantile spasms or generalized epilepsy. The
results of MRI demonstrated that all patients were found to
have cortical tubers in multiple lobes of the brain, and no patient had mesial temporal sclerosis. Other MRI findings can
be found in Table 1. All patients underwent intracranial monitoring evaluation. Three of the five patients had the RNS
System placed at the same surgery as intracranial monitoring
electrode removal.
The median baseline seizure frequency was 12 disabling
seizures per month (mean: 33.6, range: 2-88 seizures). The
median reduction in disabling seizures was 58% at 1 year
(mean: 62%, range: 42%-95%) and 88% (mean: 83%, range:
58%-95%) at last follow-up post–RNS implant. The median
follow-up duration post–RNS implantation was 17 months
(range: 9-
33 months). All five patients were responders,
defined as a 50% or greater reduction in clinically disabling
seizures at last follow-up. Three of the five patients experienced some period of seizure freedom ranging from less
than 3 months to over 1 year. All patients were categorized as
“Much Improved” or “Very Much Improved” on the CGIS.
The individual reductions in disabling seizures at year one
and last follow-up can be found in Figure 1. One patient
(patient 2) was able to reduce their ASMs from two medications to one medication. All other patients remained on the
same number of ASMs throughout the period of follow-up
reviewed.
There were no serious adverse events reported in any
patient. Stimulation-related side effects were noted in two
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F I G U R E 1 Patient seizure frequency
reduction at 1 y and last follow-up
appointment compared with preimplantation
baseline

patients (patient 4 and 5). Patient 4 had intermittent intense
left periorbital pain and muscle twitching time locked with
stimulation suggesting meningeal irritation; pain subsided
with decreased stimulation parameters. Patient 5 would occasionally report right hand dysesthesias when stimulation was
delivered to electrodes placed in the centromedian nucleus of
the thalamus. The patient elected to continue with the stimulation as it was not considered bothersome.
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D IS C U SS ION

This is the first report of TSC-DRE treated with brain-
responsive neurostimulation. The five patients in our cohort experienced median reductions in clinical seizures
of 58% at 1 year and 88% at last follow-up with the RNS
System. The RNS System implantation procedure and responsive stimulation delivery were without complication
in this small cohort.
Resective surgery can be successful in TSC patients
who have a single seizure focus and/or a MRI lesion that is
concordant with the seizure focus. However, TSC patients
frequently have more than one seizure focus. Over 40%
of TSC patients that undergo resective surgery continue
to have seizures.12 Two of the patients in our cohort had
prior resective surgery with continued seizures. The RNS
System can be used in combination with a resective procedure if some tissue can be safely resected but other cortex
involved in the seizure-onset region is eloquent or unresectable. Additionally, the electrographic seizure data gathered
by the RNS System can guide future resective surgery.13,14
Epilepsy surgery evaluations often uncover regional seizure networks in TSC patients that may involve more than
one epileptogenic tuber, the rim of the tuber, and the cortex
overlying the tuber.15,16 The RNS System offers the flexibility of treating two distinct seizure foci11 or larger regional
neocortical seizure foci.17,18 The neurostimulator can be

connected to two depth and/or cortical strip leads at one time
and up to four leads (at most two depth leads) can be placed.
The additional leads are reserved for future connection to the
neurostimulator if desired. The depth leads have two electrode spacing options which allow the targeting of a small
structure (such as a tuber) with a compact spacing (four electrodes, 3.5 mm center-to-center distance) or a broader area
(such as a tuber and its overlying cortex) with a longer spacing (10 mm center-to-center distance). In our case series, the
RNS System was used successfully to treat patients with dual
foci and patients with a single broad region of seizure onset.
Seizure outcomes in patients that have undergone epilepsy surgery for TSC-DRE decrease over time from 75%
seizure freedom at 1 year to 48% at 10 years.19 In contrast,
the RNS System clinical trials demonstrated an improvement
in clinical seizures over time, a median of 44% reduction at
1 year20 to 75% at 9 years.10 A recent posttrial report of real-
world outcomes reported similar improvements over time but
with larger improvements observed earlier in the course of
treatment, a median of 67% at 1 year to 82% at 3 or more
years.21 Our patients experienced reductions similar to that
of the published real-world study, with a median reduction in
seizures of 58% at 1 year and a median of 88% in an average
follow-up of 20 months.
The RNS System recently received FDA approval for
MRI conditional labeling, allowing patients with a RNS®
Neurostimulator model RNS-320 to undergo a 1.5T full-body
MRI scan under certain conditions. This new labeling makes
it possible for patients with TSC to be treated with brain-
responsive neurostimulation while still allowing MRI scans
to monitor brain and other organ tuber growth.
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Study limitations

This case series is limited by a small sample size and retrospective design. The retrospective nature of a chart review

MCDERMOTT et al.

has potential to bias data reporting. It should be noted that
while it is fairly common to have generalized seizure types
in TSC, the FDA approved indication for use for the RNS
System necessitated that our group of patients had focal epilepsy. The safety and efficacy of the RNS System treatment
of TSC patients should continue to be evaluated in additional
patients.
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CO NC LU SION

These data suggest that brain-responsive neurostimulation
with the RNS System can be a safe and appropriate therapeutic option for the management of refractory epilepsy in
some patients with drug-resistant epilepsy related to tuberous
sclerosis complex.
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